Abstract:The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune related [immune-related adverse events (irAEs)], notably mediated by the triggering of cytotoxic CD4+/CD8+ T cell activation. Cutaneous toxicities appear to be one of the most prevalent irAEs, both with anti-PD-1 and anti-CTLA-4 agents or with the newly developed anti-PD-L1 agents, which corresponds to a class effect. They are observed in more than one-third of the treated patients, mainly in the form of a maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. A wide range of other dermatologic manifestations can also occur, including lichenoid reactions, psoriasis, acneiform rashes, vitiligo-like lesions, autoimmune skin diseases (e.g., bullous pemphigoid, dermatomyositis, alopecia areata), sarcoidosis or nail and oral mucosal changes. In addition, the use of anti-CTLA-4 and anti-PD-1 therapies in combination is associated with the development of more frequent, more severe and earlier cutaneous irAEs compared to single agents. In most cases, these dysimmune dermatologic adverse events remain self-limiting and readily manageable. Early recognition and adequate management, however, are critical to prevent exacerbation of the lesions, to limit treatment interruption and to minimize quality of life impairment. This review describes the variable clinical and histopathologic aspects of dermatologic irAEs induced by immune checkpoint inhibitors. Appropriate treatment and counseling are also proposed, with a step-by-step approach for optimized management by both practicing oncologists and dermatologists.

Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

[Managing the Adverse Effects Related to Immune Checkpoint Inhibitors]

Toxicity in the era of immune checkpoint inhibitor therapy

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy

What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?

Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations

[The pathology of adverse events with immune checkpoint inhibitors]

Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers

Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text]

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Common endocrine system adverse events associated with immune checkpoint inhibitors

Immune-related adverse events in various organs caused by immune checkpoint inhibitors

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update

Mucocutaneous adverse events to immune checkpoint inhibitors

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Advances in Immune Checkpoint Inhibitors Induced-Cardiotoxicity